Novartis initiates clinical study of Jakavi in severe COVID-19 patients and establishes international compassionate use program. – Novartis + Incyte Corpn.
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe… read more.